2465: Dual-target CD19/BCMA CAR-T in refractory SLE (Phase 1) 🔹All pts (n=10) met SRI-4 by wk24 🔹DORIS remission: 5 (wk24), 6 (wk36–48) 🔹Residual proteinuria (n=4); renal bx (n=3) showed resolved IC deposits & inflammation 🔹CRS Grade 1 (n=6); no ICANS @RheumNow #ACR25

#SLE #DORIS #remission is RARE and without #prednisone even rarer #ASIA #Pacific 5K pts over 10 yrs A call to do better 82% LLDAS, 70% remission, 31% GC-free remission (REM-0) at least once abst#595 @ACRheum @RheumNow #ACRBest https://t.co/OK6sYnqs81

• https://x.com/Janetbirdope/status/1983662590426554571/photo/1

#Urinary #biomarkers #lupus #nephritis #Tenascin C -suggests repair, fibrosis, progress of #LN #IL16, #CD163, & more for LN activity Sometime a biomarker may replace repeat #kidney #biopsies? #AMP group #Accelerated #Medicines #Program #ACR24 @ACRheum @RheumNow abst#851

When should you order a renal bx in suspected #LN? Active urinary sediment Used to be #UPCR 500g/g or more Abst#772 looked at UPCR 250g/g to 499 71% + LN and half needed Rx esp if Low C3,C4 Black race Petri, Baltimore #lupus #cohort #ACR25 @ACRheum @RheumNow

CAR-T Cell Therapies Show Promise for Autoimmune Disease Two pioneering studies presented at #ACR25 spotlight the potential of CAR-T cell therapies to transform treatment for SLE and other autoimmune diseases. These early findings suggest a new frontier in immune modulation and https://t.co/KdNWmVc4Qc

Abstract 2694: Neutrophil:Lymphocyte ratio (NLR)- a practical step towards clinical monitoring of interferon? Log₂NLR significantly correlated with all three IFN signatures across patients with SLE, systemic sclerosis, rheumatoid arthritis, and myositis @RheumNow #ACR25 https://t.co/ujaOQGvAUV

• https://x.com/AkhilSoodMD/status/1983594626222354713/photo/1

TAC+MMF + GC vs TAC +GC in lupus nephritis (target trial emulation): 🔹Higher total renal response w/ TAC + MMF + GC at 12 mo (59.7% vs 33.3%) consistent in ITT & per-protocol 🔹similar adverse events reported (14.6% vs 16.4%) @RheumNow #ACR25 https://t.co/Yuql3O9C8X

• https://x.com/AkhilSoodMD/status/1983590907095011839/photo/1

Sooner May Still Be Too Late: Kidney Biopsies in SLE #ACR25 kicked off with Plenary Session by Michelle Petri (Abstract 0772: Redefining When to Biopsy the Kidney in Patients with SLE. As part of a collaboration with the Accelerating Medicines Partnership, Petri and colleagues https://t.co/bU09vpcDew

#2659 In a large real-world target trial (>1.3M with T2D), SGLT2 inhibitors, esp dapagliflozin & empagliflozin, were assoc with lower risks of RA, lupus, vasculitis & other autoimmune rheumatic diseases vs DPP-4 inhibitors. Possible immune benefits of SGLT2i? @RheumNow #ACR25

#ACR25 Abstr#2697 H2H RCT of Tacrolimus + GC vs MMF + GC in #lupus Nephritis in Asia for Induction-Maintenance showed similar efficacy. Different side effects: AKI more in TAC, low WCC & infections in MMF. Informative for services with no access to biologics/Voclosporin @RheumNow https://t.co/V4uWhuqjjW

• https://x.com/Yuz6Yusof/status/1983578834315157825/photo/1

Abst 2694: Post-hoc analysis of Phase 2 PAISLEY SLE trial examined impact of deucravacitinib on renal dysfunction 🔹 Plasma proteins a/w ↑ BILAG renal score and ↓ UPCR --> reduced by WK 32 🔹 Biomarkers inversely related to eGFR were reduced with deucra vs PBO @RheumNow #ACR25 https://t.co/6CvmQ9lCfS

• https://x.com/AkhilSoodMD/status/1983576311118389425/photo/1
• https://x.com/AkhilSoodMD/status/1983576311118389425/photo/1

#ACR25 Clinical Preview by Prof Coates to be applied tomorrow! GC #steroid burden & Mx Abstr#738 Survey of #GCA patients in US & EU: 3/4 were still on GC; mean 5.3mg/d Abstr#1526 International consensus of GC taper in #SLE is available & can be applied in clinic @RheumNow https://t.co/paw7NGjs4p

• https://x.com/Yuz6Yusof/status/1983560828860465223/photo/1
• https://x.com/Yuz6Yusof/status/1983560828860465223/photo/1

Thank you @drdavidliew & @DrLauraCoates ❤️ for highlighting our work. Super-responders (some were IS-Free) do exist with rituximab in #SLE Abstr#1525 @RheumNow https://t.co/S4mMAYInfT

• https://twitter.com/drdavidliew/status/1983555936657854811

@Yuz6Yusof gets a shout out from Laura Coates in the #ACR25 meeting review for his work on rituximab super-responders in SLE @RheumNow https://t.co/EKUgmENesX

• https://x.com/drdavidliew/status/1983555936657854811/photo/1
• https://x.com/drdavidliew/status/1983555936657854811/photo/1